I last reviewed Genuine Parts Company (GPC) at which time I recommended that its status as a Dividend King not influence investment decisions. Fixating on dividend metrics is a fundamentally flawed way of investing. The focus should be on a company's total potential shareholder return. On July 24, 2017, I initiated a 300 share GPC [...]
At the time of my prior Cintas post (CTAS), the most currently available financial information was for Q3 and YTD2025. Fast forward and we now have Q4 and FY2025 results and FY2026 outlook thus prompting me to revisit this existing holding. Business Overview Part 1 Item 1 in the FY2024 Form 10-K and the [...]
At the time of my April 25, 2025 Thermo Fisher (TMO) – Headwinds Present A Buying Opportunity post, it had just released its Q1 2025 results and FY2025 guidance. In that post, I disclosed the purchase of: a few TMO shares @ ~$431.03/share in a 'Core' account in the FFJ Portfolio on April 17, 2025; [...]
Rollins (ROL) may not appeal to some investors because the nature of its business is not 'sexy'. Sometimes, however, 'ho hum' businesses can offer investors the potential for very reasonable long-term total shareholder returns. Through its family of brands, ROL provides pest control, termite services and wildlife removal to residential and commercial customers. Looking at [...]
Following the release of Accenture's (ACN) Q3 and YTD2025 results on June 20, 2025, the share price plunged to ~$284 from the prior day's ~$306.50 closing share price. This prompted me to look at its results and outlook. Based on my analysis, I initiated a 200 share position @ ~$284.58 in one of the 'Core' [...]
Copart's valuation improves despite no fundamental change in the company's long term outlook. I have, therefore, acquired an additional 200 shares @ ~$48.12 in a 'Core' account in the FFJ Portfolio on June 18. This is a brief post because I covered CPRT as recently as May 28, 2025 where I disclose the purchase of [...]
Intuitive Surgical (ISRG) is redefining the future of surgery with innovation. Its da Vinci platform ranks as being one of the most disruptive technologies in medtech history thus leading to the company's remarkable success in rewarding long-term shareholders. I last reviewed ISRG in this January 25, 2025 post at which time shares were trading at [...]
In my Why I Added Howard Hughes Holdings (HHH) To The FFJ Portfolio post, I disclose the purchase of 500 HHH shares @ $68.074 on June 3, 2025 in one of the 'Core' accounts in the FFJ Portfolio. Upon further reflection, I acquired another 500 shares on June 5 @ $67.7237. My total HHH [...]
I have previously looked at Howard Hughes Holdings (HHH) but very quickly determined I wanted no exposure. I now have a different perspective because the historical HHH will not resemble HHH of the future. So what has changed? In this May 2025 interview, Bill Ackman (the founder and CEO of Pershing Square Capital Management) provides [...]
I last reviewed Agilent (A) in this February 28, 2025 post at which time the most current financial information was for Q1 2025. With the recent release of Q2 and YTD2025 results and an update to the FY2025 outlook, I revisit this existing holding. Business Overview A has the following 3 reportable business segments: life [...]